Remdesivir: Covid drug taken by Trump has ‘little to no effect’, says WHO
The U.N. health agency says the world’s largest randomized trial of COVID-19 treatments found “conclusive evidence” that remdesivir, a drug used to treat U.S. President Donald Trump when he fell ill, has little or no effect on severe cases
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The U.N. health agency says the world's largest randomized trial of COVID-19 treatments found “conclusive evidence” that remdesivir a drug used to treat U.S. President Donald Trump when he fell ill, has little or no effect on severe cases.
The World Health Organization announced Friday the long-awaited results of its six-month “Solidarity Therapeutics Trial” that endeavored to see if existing drugs might have an effect on the coronavirus.
The study, which was not peer-reviewed, found that four treatments tested — remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon — had “ little or no effect" on whether or not patients died within about a month or whether hospitalized patients recovered.
Most of those had already been ruled out. But remdesivir, a repurposed malaria drug, has been classified as standard-of-care in the United States, and it has been approved for use against COVID-19 in the UK and EU. Supplies of the drug have been limited, and the European Medicines Agency is now reviewing whether remdesivir is causing kidney problems as reported by some patients.
Martin Landray, a professor of medicine and epidemiology at Oxford University, said the WHO trial results for hydroxychloroquine and lopinavir were in line with a previous British study he co-led.
“The big story is the finding that remdesivir produces no meaningful impact on survival,” he said in a statement. He said the drug is now recommended in some countries but there have been significant concerns about supply, cost and access.
“This is a drug that has to be given by intravenous infusion for 5 to 10 days,” noting it costs about $2,550 per treatment course. “COVID affects millions of people and their families around the world. We need scalable, affordable, and equitable treatments."
A cocktail of treatments given to President Trump after he tested positive for the coronavirus included remdesivir.
WHO said the study, which covered more than 30 countries, looked at the effects of the treatments on overall death rates, whether or not patients need breathing machines, and how much time patients spent recovering in hospitals.